Program
opugotamig olatansine
In AbbVie’s pipeline, FR-alpha
. Its studies are mostly in Fallopian Tube Neoplasms · Endometrial Neoplasms, led by AbbVie.
Furthest: phase 2, since Jun 9, 20252 company-led studies, 2 open or runningNext primary completion: Feb 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVie | 22 open or running | phase 2since Jun 9, 2025 | Aug 23, 2022 | Feb 2027phase 1 · NCT05527184 |
- Named in AbbVie’s own pipeline as
IMGN-151
, phase 2, as of Jul 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 23, 2022First study: phase 1 study in Endometrial NeoplasmsFirst studyNCT05527184 · 256 enrolled · United States, Australia, Belgium and more
- Jun 9, 2025Phase 2 study in Fallopian Tube NeoplasmsNCT07024784 · 377 planned · United States, Israel, Japan
Ahead
- Feb 2027Primary completion: phase 1 study in Endometrial NeoplasmsNCT05527184
- Jan 2028Primary completion: phase 2 study in Fallopian Tube NeoplasmsNCT07024784
TargetBeta
“FR-alpha”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of opugotamig, an asymmetric, bivalent, biparatopic antibody targeting two independent epitopes of folate receptor alpha (FRa; FolRa; FOLR1) that is ”NCIt, by rule
Other programs on FOLR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| mirvetuximab soravtansinerule | AbbVie | phase 3 | 15 |
| rinatabart sesutecanrule | Genmab | phase 3 | 9 |
| torvutatug samrotecan | AstraZeneca | phase 3 | 5 |
| sofetabart mipitecan | Eli Lilly | phase 3 | 2 |
| Anti-Folate Receptor Alpha Antibody-drug Conjugate ABBV-901 | AbbVie | phase 1 | 1 |
| Anti-FRa/Anti-CD3 Bispecific TCE NTB-928rule | teneoseven-inc | phase 1 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07024784Fallopian Tube Neoplasms · United States, Israel, Japan | 2 | Recruiting | Jan 2028 | 377 |
| NCT05527184Endometrial Neoplasms · United States, Australia, Belgium and more | 1 | Active, not recruiting | Feb 2027 | 256 |
How it is read
Names in the registry
- “IMGN151”, 2 entries
Conditions, from the studies’ own filings
- Fallopian Tube Neoplasms, 1 study
- Endometrial Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.